Simpler stem cell collection could ease donor burden in Life-Threatening anemia

NCT ID NCT07629947

Not yet recruiting Disease control Sponsor: Peking University People's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This trial tests whether using only blood stem cells (instead of blood stem cells plus bone marrow) for a half-matched transplant is safe and effective for severe aplastic anemia. 180 patients aged 18-40 will be randomly assigned to one of two graft sources. The main goal is to see if the simpler method leads to similar rates of graft-versus-host disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: stem cell transplant (using donor blood stem cells, with or without bone marrow)
What this could lead to: If successful, this could make stem cell transplants for severe aplastic anemia simpler and less invasive for donors, while keeping the same level of safety and effectiveness for patients.
What could go wrong: This is an early-stage trial (not yet recruiting) with 180 participants, so results may not apply to everyone. Using only blood stem cells might increase the risk of graft-versus-host disease, a serious complication.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEVERE APLASTIC ANEMIA (SAA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired aplastic anemia aplastic anemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SEVERE APLASTIC ANEMIA (SAA)

More trials for these conditions

Other studies related to the condition(s) this trial covers.